Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis

Table 2

The distribution pattern of aggrecan turnover markers and antioxidant defense system in control subjects and juvenile idiopathic arthritis patients.

Parameter	Control group; ()	Nontreated JIA patients; ()	JIA patients after treatment and attainment of clinical improvement; ()
CS (hexuronic acids, mg/L)	87.00 ± 21.94	42.45 ± 13.35	73.70 ± 15.53
CS846 (ng/mL)	152.52 ± 79.72	231.96 ± 50.84	165.88 ± 76.80
CT (U Bergm/g Hb)	58.84 ± 4.51	95.05 ± 16.43	70.98 ± 21.12
SOD (U/g Hb)	759.36 ± 176.43	1049.08 ± 162.45	720.65 ± 141.09
GPx (U/g Hb)	33.95 ± 8.51	47.85 ± 6.51	36.95 ± 6.62

Results are expressed as mean ± SD; and compared to control group; and compared to untreated JIA patients.
JIA, juvenile idiopathic arthritis; CS, chondroitin sulfate; CS846, chondroitin sulfate 846 epitope; CT, catalase; SOD, superoxide dismutase; GPx, glutathione peroxidase.